tumor lysis syndrome

Summary

Summary: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Top Publications

  1. ncbi Tumor lysis syndrome
    S Jeha
    Department of Pediatrics, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 38:4-8. 2001
  2. ncbi Pharmacological treatment of acute renal failure in intensive care unit patients
    Delphine Moreau
    Medical Intensive Care Unit, CHU Gabriel Montpied, Clermont Ferrand, France
    Contrib Nephrol 147:161-73. 2005
  3. ncbi The management of tumor lysis syndrome
    Elvira Rampello
    Department of Senescence, Urological and Neurological Sciences, Catania University, Catania, Italy
    Nat Clin Pract Oncol 3:438-47. 2006
  4. ncbi Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome
    Kyung A Choi
    Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, South Korea
    Ann Hematol 88:639-45. 2009
  5. ncbi How we treat tumor lysis syndrome
    Alaa Muslimani
    Department ofHematology Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA
    Oncology (Williston Park) 25:369-75. 2011
  6. ncbi Tumour lysis syndrome: new therapeutic strategies and classification
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Br J Haematol 127:3-11. 2004
  7. ncbi Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature
    Brett Riccio
    Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
    Cancer Biol Ther 5:1614-7. 2006
  8. ncbi Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
    Pau Montesinos
    Hematology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46019, Valencia, Spain
    Haematologica 93:67-74. 2008
  9. ncbi Spontaneous tumor lysis syndrome in a child with T-cell acute lymphoblastic leukemia
    Daisuke Kobayashi
    Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Pediatr Blood Cancer 54:773-5. 2010
  10. pmc Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    K A Blum
    Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
    Leukemia 25:1444-51. 2011

Research Grants

  1. Preclinical Development of Uricase-PEG 20
    JOHN BOMALASKI; Fiscal Year: 2002
  2. Nonablative AlloSCT in Refractory Autoimmune Disease
    Mitchell Cairo; Fiscal Year: 2003
  3. First Int'l Symposium on Childhood and Adolescent NHL
    Mitchell Cairo; Fiscal Year: 2003
  4. A Phase I Study of Single Agent Flavopiridol in B-Cell *
    Thomas Lin; Fiscal Year: 2007
  5. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2006
  6. A Novel Dosing Schedule of Flavopiridol in CLL
    Thomas Lin; Fiscal Year: 2006
  7. A Phase I Study of the AKT Inhibitor 17-AAG in CLL
    Thomas Lin; Fiscal Year: 2006
  8. Antiproliferative Rx for venous neointimal hyperplasia
    Prabir Roy Chaudhury; Fiscal Year: 2005
  9. PEDIATRIC ONCOLOGY GROUP
    Yaddanapudi Ravindranath; Fiscal Year: 2002
  10. Monoclonal Antibody Therapy in B-Cell CLL.
    Thomas Lin; Fiscal Year: 2008

Detail Information

Publications223 found, 100 shown here

  1. ncbi Tumor lysis syndrome
    S Jeha
    Department of Pediatrics, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 38:4-8. 2001
    b>Tumor lysis syndrome (TLS) is a constellation of metabolic disturbances observed in tumors with high cell turnover. It is associated with significant morbidity and mortality...
  2. ncbi Pharmacological treatment of acute renal failure in intensive care unit patients
    Delphine Moreau
    Medical Intensive Care Unit, CHU Gabriel Montpied, Clermont Ferrand, France
    Contrib Nephrol 147:161-73. 2005
    ..nevertheless, hematological, when patients with large tumor burden and rapid cell turnover develop acute tumor lysis syndrome (ATLS)...
  3. ncbi The management of tumor lysis syndrome
    Elvira Rampello
    Department of Senescence, Urological and Neurological Sciences, Catania University, Catania, Italy
    Nat Clin Pract Oncol 3:438-47. 2006
    The manifestation of tumor lysis syndrome (TLS) occurs when the destruction of tumor cells releases breakdown products that overwhelm the excretory mechanisms of the body. A cardinal sign is hyperuricemia, leading to uric acid nephropathy...
  4. ncbi Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome
    Kyung A Choi
    Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, South Korea
    Ann Hematol 88:639-45. 2009
    b>Tumor lysis syndrome (TLS) is a potentially fatal metabolic complication of chemotherapy for Burkitt lymphoma...
  5. ncbi How we treat tumor lysis syndrome
    Alaa Muslimani
    Department ofHematology Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA
    Oncology (Williston Park) 25:369-75. 2011
    b>Tumor lysis syndrome (TLS) is an oncology emergency that occurs as a result of rapid tumor cell breakdown and the consequent release of massive amounts of intracellular contents, including potassium, phosphate, and uric acid, into the ..
  6. ncbi Tumour lysis syndrome: new therapeutic strategies and classification
    Mitchell S Cairo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
    Br J Haematol 127:3-11. 2004
    ..We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme...
  7. ncbi Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature
    Brett Riccio
    Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
    Cancer Biol Ther 5:1614-7. 2006
    Spontaneous tumor lysis syndrome (TLS) is a constellation of electrolyte abnormalities and acute renal failure, which occurs in the setting of rapid cell turnover prior to the administration of cytotoxic chemotherapy...
  8. ncbi Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
    Pau Montesinos
    Hematology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46019, Valencia, Spain
    Haematologica 93:67-74. 2008
    Despite the prophylactic use of allopurinol, tumor lysis syndrome (TLS)-related morbidity and mortality still occur in a number of patients with acute myeloid leukemia (AML)...
  9. ncbi Spontaneous tumor lysis syndrome in a child with T-cell acute lymphoblastic leukemia
    Daisuke Kobayashi
    Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Pediatr Blood Cancer 54:773-5. 2010
    ..Our case was the fifth and the youngest case of ALL with spontaneous tumor lysis syndrome. However, in contrast to previous reports in ALL or acute myeloid leukemia, our patient did not have blasts ..
  10. pmc Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    K A Blum
    Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
    Leukemia 25:1444-51. 2011
    b>Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol...
  11. ncbi Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma
    Mark Lipstein
    University of Rochester, New York, NY, USA
    Clin Lymphoma Myeloma Leuk 10:E43-6. 2010
    ..Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.
  12. ncbi Prevention of tumor lysis syndrome in an outpatient setting
    Tammy Mackiewicz
    School of Nursing, University of South Florida in Tampa, USA
    Clin J Oncol Nurs 16:189-93. 2012
    The prevention and identification of hyperuricemia are critical components in the management of tumor lysis syndrome (TLS), which is common in acute leukemias, large cell lymphomas, bulky tumors, large tumor burdens, and other cancers ..
  13. ncbi Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma
    Yoshiyuki Nakamura
    Department of Dermatology, University of Tsukuba, Japan
    Int J Dermatol 48:763-7. 2009
    b>Tumor lysis syndrome (TLS) is rare in the treatment of solid tumors, but it may occur in myelolymphoproliferative diseases.
  14. ncbi Tumor lysis syndrome in small cell lung cancer
    A M Kallab
    Department of Medicine, Section of Hematology Oncology, Medical College of Georgia, Augusta, USA
    Med Oncol 18:149-51. 2001
    b>Tumor lysis syndrome, resulting from the abrupt release of intracellular ions into the blood stream due to sudden tumor cell death, is a serious complication of chemotherapy treatment...
  15. ncbi Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma--a case report
    S M Ahamed
    Department of Pathology, Jawaharlal Institute of Post Graduate Medical Education and Research JIPMER, Pondicherry
    Indian J Pathol Microbiol 49:26-8. 2006
    ..This rare occurrence was encountered in a patient with non-Hodgkin's lymphoma (NHL), of follicular cell type. Conservative but intensive treatment led to complete resolution. Subsequent chemotherapy was well tolerated...
  16. ncbi Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 23:6794-5. 2005
  17. ncbi Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report
    Kazue Shiozawa
    Department of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, Tokyo, Japan
    Hepatogastroenterology 57:688-90. 2010
    ..marked renal impairment and hyperuricemia in a short period after sorafenib administration, which suggested tumor lysis syndrome (TLS)...
  18. ncbi Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma
    Rachel S Bercovitz
    Center for Cancer and Blood Disorders, The Children s Hospital, 13123 East 16th Ave Box B115, Aurora, CO 80045, USA
    Curr Opin Pediatr 22:113-6. 2010
    Acute tumor lysis syndrome (TLS) is characterized by the triad of hyperuricemia, hyperkalemia, and hyperphosphatemia and is caused by the death of tumor cells and release of intracellular contents into the circulation...
  19. ncbi Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma
    Judith Michels
    Institut Gustave Roussy, Departement de Medecine, Villejuif, France
    Invest New Drugs 28:690-3. 2010
    ..Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.
  20. ncbi Metastatic gestational trophoblastic neoplasia complicated by tumor lysis syndrome, heart failure, and thyrotoxicosis: a case report
    Samer Schuman
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, Florida, USA
    J Reprod Med 55:441-4. 2010
    b>Tumor lysis syndrome (TLS) is an extremely rare complication of solid tumors and is more frequently observed in patients with hematologic malignancies...
  21. ncbi Tumor lysis syndrome in an infant with Langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration
    T H Jaing
    Department of Medicine, Chang Gung Children s Hospital, Taoyuan, Taiwan
    J Pediatr Hematol Oncol 23:142-4. 2001
    Langerhans cell histiocytosis (LCH) is an enigmatic disease usually occurring in children. Tumor lysis syndrome (TLS) is a clinical syndrome associated with severe metabolic derangement and oliguric acute renal failure...
  22. ncbi Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer
    A Y Rostom
    The Royal Marsden Hospital, Sutton, Surrey, UK
    Ann Oncol 11:1349-51. 2000
    b>Tumor lysis syndrome (TLS) is a rare serious acute complication of cancer therapy, reported mainly following chemotherapy in patients with large tumor load and chemosensitive disease...
  23. ncbi Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
    Philip J Saylor
    Department of Oncology, University of California, San Diego, CA, USA
    J Clin Oncol 25:3544-6. 2007
  24. ncbi Management of pediatric tumor lysis syndrome in the emergency department
    Mark R Zonfrillo
    Division of Emergency Medicine, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Emerg Med Clin North Am 27:497-504. 2009
    b>Tumor lysis syndrome is most often seen after the treatment of blood and solid malignancies. The resultant hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia can lead to life threatening complications...
  25. ncbi Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Cutan Pathol 31:274-80. 2004
    ..is presented, who developed slate bluish-gray to brown discoloration of her skin after chemotherapy-induced tumor lysis syndrome. A number of studies were performed to re-evaluate possible mechanisms of melanosis...
  26. ncbi Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients
    Ashleigh N Vines
    University of Maryland, Baltimore, USA
    Ann Pharmacother 44:1529-37. 2010
    ..management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia. The labeled dose is 0...
  27. ncbi Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma
    Cheng Jui Lin
    Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, 92 Chung San North Road Section 2, Taipei, Taiwan
    Med Oncol 24:455-7. 2007
    b>Tumor lysis syndrome is a set of life threatening complication that can arise from treatment of high tumor burden, drug sensitive, and rapidly proliferating neoplasm particularly of hematological origin...
  28. ncbi Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma
    Hiroaki Shiba
    Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
    Cancer Sci 99:2104-5. 2008
    ..After treatment, the patient developed acute tumor lysis syndrome with hyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia, metabolic acidosis and acute renal ..
  29. ncbi Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management
    Ali K Abu-Alfa
    Yale University School of Medicine, New Haven, CT 06520 8029, USA
    Am J Kidney Dis 55:S1-13; quiz S14-9. 2010
    b>Tumor lysis syndrome (TLS) describes a constellation of biochemical and clinical abnormalities resulting from rapid and massive tumor cell death...
  30. ncbi Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study
    Jorge Cortes
    MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:4207-13. 2010
    ..This study in adults evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and with allopurinol alone in controlling plasma uric acid...
  31. ncbi Pitfalls in predicting tumor lysis syndrome
    Scott C Howard
    Department of Hematology Oncology and the International Outreach Program, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leuk Lymphoma 47:782-5. 2006
  32. ncbi Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome
    Randall W Knoebel
    Department of Pharmacy, Rush University Medical Center, Chicago, Illinois, USA
    J Oncol Pharm Pract 17:147-54. 2011
    ..reserved for the treatment or prevention of hyperuricemia in patients that are at high risk of developing tumor lysis syndrome (TLS)...
  33. ncbi Difficult diagnostic and therapeutic cases: CASE 2. thymoma and tumor lysis syndrome in an adolescent
    Angela D Trobaugh-Lotrario
    Department of Pediatric Hematology Oncology, The Children s Hospital of Denver, Denver, CO, USA
    J Clin Oncol 22:955-7. 2004
  34. ncbi Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer
    Jonathan L Wright
    Department of Urology, University of Washington, WA, USA
    Int J Urol 12:1012-3. 2005
    b>Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors...
  35. ncbi Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor
    Hassanali H Sewani
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 77:722-8. 2002
    b>Tumor lysis syndrome, caused by massive tumor cell death, is an infrequent occurrence in solid tumors, and only a few cases of tumor lysis syndrome occurring in patients with lung cancer have been reported...
  36. ncbi [Spontaneous tumor lysis syndrome in a patient with non-Hodgkin's lymphoma]
    J Barquero Romero
    Servicio de Medicina Interna, Hospital Perpetuo Socorro, Complejo Hospitalario Universitario, Badajoz
    An Med Interna 22:387-9. 2005
    ..The cytology and molecular studies of cervical adenopathy sample were diagnostic of high-grade non-Hodgkin's lymphoma. A presumptive diagnosis of non Hodgkin lymphoma with spontaneous tumor lysis syndrome was made.
  37. ncbi An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome
    Tariq I Mughal
    Department of Haematology, Guy s and St Thomas s NHS Hospital, London, UK
    Cancer Treat Rev 36:164-76. 2010
    b>Tumor lysis syndrome (TLS) is a potentially life-threatening metabolic disorder that occurs when tumor cells undergo rapid decomposition spontaneously or in response to cytoreductive therapy...
  38. ncbi Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome
    C S Chim
    Cancer Chemother Pharmacol 62:181-2. 2008
  39. ncbi Spontaneous tumor lysis syndrome in acute lymphoblastic leukemia
    Shefali Khanna Sharma
    J Assoc Physicians India 53:828-30. 2005
  40. ncbi Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach
    M Campara
    Department of Pharmacy Practice, University of Illinois, Chicago, IL, USA
    J Clin Pharm Ther 34:207-13. 2009
    ..The optimal rasburicase dose for adult patients has not been determined...
  41. ncbi Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma
    Chien Chang Lee
    Oncologist 11:87-8; author reply 89. 2006
  42. ncbi Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma
    Piper M Treuting
    Department of Comparative Medicine, University of Washington, Seattle, WA 98195 7190, USA
    Toxicol Pathol 38:476-85. 2010
    Acute tumor lysis syndrome (ATLS) is characterized by severe metabolic abnormalities and organ dysfunction resulting from rapid destruction of neoplastic cells...
  43. doi Tumor lysis syndrome: current perspective
    Jessica Hochberg
    Haematologica 93:9-13. 2008
  44. ncbi Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome
    Michael B Davidson
    Department of General Internal Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Med 116:546-54. 2004
    b>Tumor lysis syndrome is an oncologic emergency that is characterized by severe electrolyte abnormalities and, frequently, by acute renal failure...
  45. pmc Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
    Lisa Cammalleri
    Dept of Senescence, Urological and Neurological Sciences, University of Catania, Catania, Italy
    Int J Med Sci 4:83-93. 2007
    ..A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney...
  46. ncbi Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies
    Lin Yen Wang
    Division of Hematology Oncology, Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan
    Acta Haematol 115:35-8. 2006
    ..July 2003 to July 2004, recombinant urate oxidase (rasburicase) was administered to patients at risk for tumor lysis syndrome before or during the initiation of chemotherapy...
  47. ncbi Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer
    Cheng Jui Lin
    South Med J 100:916-7. 2007
  48. ncbi Transient abnormal myelopoiesis complicated by tumor lysis syndrome
    Yoshifusa Abe
    Division of Neonatology, Chiba Children s Hospital, Chiba, Japan
    Pediatr Int 48:489-92. 2006
  49. ncbi Bortezomib-induced tumor lysis syndrome in multiple myeloma
    Orhan Sezer
    Department of Hematology and Oncology, University Hospital Charite Berlin, Germany
    Clin Lymphoma Myeloma 7:233-5. 2006
    b>Tumor lysis syndrome (TLS) is exceedingly rare in multiple myeloma because of the relatively slow proliferation and response of the malignant cells...
  50. ncbi Treatment of impending tumor lysis with single-dose rasburicase
    Anselm C W Lee
    Department of Paediatrics, Tuen Mun Hospital, New Territories, Hong Kong, China
    Ann Pharmacother 37:1614-7. 2003
    ..To report the experience of using rasburicase as a single-dose treatment for childhood leukemia presenting with hyperuricemia...
  51. ncbi A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome
    Satoru Joshita
    Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan
    Intern Med 49:991-4. 2010
    ..In conclusion, clinicians should bear in mind not only the published adverse effects, but also massive tumor lysis, when treating patients with large tumor burden by sorafenib...
  52. ncbi Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
    Mitchell S Cairo
    Department of Pediatrics, Columbia University, Morgan Stanley Children s Hospital, NY Presbyterian, New York, NY, USA
    Br J Haematol 149:578-86. 2010
    ....
  53. ncbi Pediatric considerations in tumor lysis syndrome
    Lisa Truini-Pittman
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, M T835, New York, NY 10021, USA
    Semin Oncol Nurs 18:17-22. 2002
    To identify pediatric issues related to tumor lysis syndrome (TLS) focusing on potential differences in patient monitoring and management in the pediatric patient as opposed to the adult; to discuss family and caregiver education.
  54. ncbi Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?
    Eleonora Vaisban
    Department of Medicine A, Western Galilee Hospital, Naharya, Israel
    Am J Med Sci 325:38-40. 2003
    Acute tumor lysis syndrome (ATLS), which occurs spontaneously, without cytotoxic therapy, is a rare condition. Spontaneous TLS (STLS) has been seen most commonly in lymphoma and leukemia...
  55. ncbi Steroid-induced tumor lysis syndrome in a patient with preleukemia
    S S Yang
    Division of Nephrology, Department of Medicine, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
    Clin Nephrol 59:201-5. 2003
    b>Tumor lysis syndrome (TLS) is a well recognized complication of chemotherapy and radiotherapy for leukemia, lymphoma as well as rapidly growing malignancies. Less described is the occurrence of TLS following steroid therapy alone...
  56. ncbi Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report
    P Zigrossi
    U.O.A. Medicina Generale II,
    Ann Ital Med Int 16:112-7. 2001
    b>Tumor lysis syndrome, which develops after effective therapy of malignant conditions and leads to hyperuricemia, hyperkaliemia, hyperphosphatemia, hypocalcemia and elevated lactate dehydrogenase, is uncommon in solid tumors...
  57. pmc Spontaneous acute tumor lysis syndrome with advanced gastric cancer
    I S Woo
    Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea
    J Korean Med Sci 16:115-8. 2001
    Acute tumor lysis syndrome (TLS) occurs frequently in hematologic malignancies such as high-grade lymphomas and acute leukemia, which are rapidly proliferating and chemosensitive tumors...
  58. ncbi Severe spontaneous acute tumor lysis syndrome and hypoglycemia in patient with germ cell tumor
    Vito D'Alessandro
    Unit of Internal Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Tumori 96:1040-3. 2010
    b>Tumor lysis syndrome has been observed in patients with bulky, treatment-sensitive tumors, in particular hematological malignancies, especially after medical treatment (chemotherapy, corticosteroids, radiation, hormonal agents, and ..
  59. doi Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma
    Ganapathy Krishnan
    Department of Internal Medicine, Division of Hematology and Oncology, Michigan State University, East Lansing, MI, USA
    J Clin Oncol 26:2406-8. 2008
  60. ncbi Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer
    David J Reeves
    Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, Michigan 48073, USA
    Pharmacotherapy 28:685-90. 2008
    To determine the efficacy of a single 7.5-mg dose of rasburicase compared with single doses of 0.15 mg/kg for the prevention or treatment of hyperuricemia associated with tumor lysis syndrome.
  61. ncbi Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma
    Mevlut Kurt
    Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
    Med Oncol 22:203-6. 2005
    We report the case of a 52-yr-old man with metastatic lung adenocarcinoma who developed tumor lysis syndrome after administration of zoledronic acid...
  62. ncbi Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases
    G Pentheroudakis
    Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, UK
    Support Care Cancer 9:554-7. 2001
    ..Successful treatment with dialysis and chemotherapy is possible, and prophylactic vigorous hydration and allopurinol may be warranted in this setting...
  63. ncbi Tumor lysis syndrome induced by dexamethasone
    Michael Chanimov
    Anesthesiology 105:633-4. 2006
  64. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
    ..with clinical response and cytokine release syndrome, and glucuronide metabolite AUC correlated with tumor lysis syndrome. These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, ..
  65. ncbi Renal tubular damage in rasburicase: risks of alkalinisation
    H van den Berg
    Ann Oncol 15:175-6. 2004
  66. ncbi Consensus conference on the management of tumor lysis syndrome
    Patrizia Tosi
    Hematology Unit, Istituto Seragnoli, Ospedale Sant Orsola Malpighi, Bologna, Italy
    Haematologica 93:1877-85. 2008
    b>Tumor lysis syndrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in the institution of appropriate treatments...
  67. ncbi Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma
    Shannon G Lehner
    St Louis University School of Medicine, St Louis, MO, USA
    AJR Am J Roentgenol 185:1307-9. 2005
  68. ncbi Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome
    Abdurrahman Tufan
    Ann Hematol 85:183-4. 2006
  69. ncbi Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase
    Margit Hummel
    III Medizinische Klinik, Klinikum Mannheim, University of Heidelberg, Mannheim, Germany
    Eur J Haematol 75:518-21. 2005
    ..by a genetically modified Saccharomyces cerevisiae and has been approved for prophylaxis and treatment of tumor lysis syndrome in 2001. In several studies, rasburicase, given at a dose of 0.15-0...
  70. doi Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future
    Catherine Rioufol
    Onkologie 31:157-8. 2008
  71. ncbi Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia
    S Trifilio
    Pharmacy Department, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Bone Marrow Transplant 37:997-1001. 2006
    ..No significant renal dysfunction developed in any of the patients. We conclude that rasburicase is effective in lowering uric acid levels at a fixed dose of 3 mg, which is much lower than the recommended dose...
  72. ncbi Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer
    Daniel Ajzensztejn
    Department of Oncology, The Whittington Hospital NHS Trust, London, United Kingdom
    J Clin Oncol 24:2389-91. 2006
  73. ncbi Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia
    Laure A Moutouh-de Parseval
    J Clin Oncol 25:5047. 2007
  74. ncbi Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults
    Anne M McDonnell
    Department of Pharmacy Services, Medical University Hospital, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Pharmacotherapy 26:806-12. 2006
    ..once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS)...
  75. ncbi A predictive model for the detection of tumor lysis syndrome during AML induction therapy
    Anthony R Mato
    Hematologic Malignancies Program, Division of Hematology and Oncology, Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Leuk Lymphoma 47:877-83. 2006
    b>Tumor lysis syndrome (TLS) is defined by metabolic derangements occurring in the setting of rapid tumor destruction...
  76. doi Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer
    Hye Suk Han
    Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea
    J Clin Oncol 26:1006-8. 2008
  77. ncbi Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase
    Jose Manuel Calvo-Villas
    Department of Hematology, Hospital General de Lanzarote, Arrecife de Lanzarote, Spain
    Onkologie 31:197-9. 2008
    ..It has a similar tolerability profile to that of the intravenous formulation. Acute tumor lysis syndrome (TLS) induced by fludarabine appears to be a fairly unusual complication during the treatment of CLL.
  78. ncbi Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome
    Tony H Truong
    Division of Hematology Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Cancer 110:1832-9. 2007
    b>Tumor lysis syndrome (TLS) is a well-recognized complication of acute lymphoblastic leukemia (ALL). The ability to predict children at differing risk of TLS would be an early step toward risk-based approaches...
  79. ncbi Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH
    Pornpimol Rianthavorn
    Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Pediatr Nephrol 23:1367-70. 2008
    ..It proved to be an important component in preventing uric acid nephropathy/tumor lysis syndrome. Conivaptan induced free-water clearance as indicated by increased urine output and decreased urine ..
  80. ncbi Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization
    Andrew B Leibowitz
    Departments of Anesthesiology, The Mount Sinai School of Medicine, New York, NY 10020, USA
    Surg Laparosc Endosc Percutan Tech 17:210-1. 2007
    ..The patient recovered fully after suffering acute renal failure requiring dialysis for 6 weeks postoperatively. Caution using this approach is necessary to avoid this rare and potentially lethal complication...
  81. ncbi Tumor lysis syndrome
    Ramon V Tiu
    Internal Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Semin Thromb Hemost 33:397-407. 2007
    b>Tumor lysis syndrome (TLS) is an important metabolic disorder frequently encountered in the management of a variety of cancers including lymphoma, leukemia, and neuroblastoma...
  82. ncbi Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review
    Bertrand Coiffier
    Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France
    J Clin Oncol 26:2767-78. 2008
    b>Tumor lysis syndrome (TLS) has recently been subclassified into either laboratory TLS or clinical TLS, and a grading system has been established...
  83. ncbi Management of tumor lysis syndrome in adults
    Bertrand Coiffier
    Centre Hospital Lyon Sud, Department of Hematology, 69310 Pierre Benite, France
    Expert Rev Anticancer Ther 7:233-9. 2007
    Spontaneous or treatment-induced tumor lysis syndrome (TLS) can cause significant morbidity and potential mortality...
  84. ncbi Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma
    Noriaki Sakamoto
    Department of Radiology, Hyogo Medical Center for Adults, 13 70 Kitaoji, Akashi City, Hyogo, 673 8558, Japan
    Cardiovasc Intervent Radiol 30:508-11. 2007
    Acute tumor lysis syndrome results from a sudden and rapid release of products of cellular breakdown after anticancer therapy. Severe alterations of metabolic profile might occur and result in acute renal failure...
  85. ncbi Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase
    A Vora
    Ann Oncol 13:1833-4. 2002
  86. ncbi Hypoglycemia and tumor lysis syndrome associated with peritoneal mesothelioma in a horse
    Alison M Lacarrubba
    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA
    J Vet Intern Med 20:1018-22. 2006
  87. ncbi Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis
    Robyn J Macfarlane
    Dalhousie University Medical School, Dalhousie University, Halifax, Nova Scotia, Canada
    Pediatr Nephrol 19:924-7. 2004
    ..We conclude that WBC reduction strategies may not be required solely for the risk of tumor lysis syndrome in patients with very high WBC (>200 x 10(9)/l) who are treated with rasburicase.
  88. ncbi Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002
    P M Navolanic
    Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA
    Leukemia 17:499-514. 2003
    Renal precipitation of uric acid associated with tumor lysis syndrome (TLS) is a major complication in the management of leukemia, lymphoma, and other drug-sensitive cancers...
  89. ncbi Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica
    Andrea Pession
    Oncoematologia Pediatrica, Dipartimento di Scienze Pediatriche Mediche e Chirurgiche, Universita di Bologna, Policlinico S Orsola Malpighi, Bologna, Italy
    Contrib Nephrol 147:80-92. 2005
    Hyperuricemia and tumor lysis syndrome (TLS) are complications that can arise from treatment of rapidly proliferating and drug-sensitive neoplasms...
  90. ncbi Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome
    Sima Jeha
    St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Contrib Nephrol 147:69-79. 2005
    Spontaneous or treatment-induced tumor lysis syndrome (TLS) can cause significant morbidity and potential mortality...
  91. ncbi Acute tumor lysis syndrome in solid tumors--a case report and review of the literature
    L Baeksgaard
    Department of Oncology, National University Hospital, 9 Blegdamsvej, DK 2100, Copenhagen, Denmark
    Cancer Chemother Pharmacol 51:187-92. 2003
    b>Tumor lysis syndrome (TLS) is a potential complication in cancer therapy. It may occur in highly sensitive tumors, especially in childhood cancers and acute leukemias, whereas it is rare in the treatment of adult solid tumors...
  92. ncbi Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies
    Raul C Ribeiro
    The Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Clin Lymphoma 3:225-32. 2003
    ..accompanied by other metabolic abnormalities and/or organ failure, hyperuricemia may be a manifestation of tumor lysis syndrome (TLS)...
  93. ncbi Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients
    L Annemans
    HEDM Health Economics and Disease Management, Brusselsesteenweg 91, 1860, Meise, Belgium
    Support Care Cancer 11:249-57. 2003
    ..The objective was to assess incremental cost-effectiveness ratios (ICER) of preventing/treating HU and TLS with recombinant urate oxidase, rasburicase (Fasturtec/Elitek)...
  94. ncbi Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
    Bertrand Coiffier
    Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
    J Clin Oncol 21:4402-6. 2003
    Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin's lymphomas (NHLs)...
  95. ncbi Role of i.v. allopurinol and rasburicase in tumor lysis syndrome
    Mark T Holdsworth
    College of Pharmacy, University of New Mexico, 2502 Marble, NE, Albuquerque, NM 87131 5691, USA
    Am J Health Syst Pharm 60:2213-22; quiz 2223-4. 2003
    The role of i.v. allopurinol and rasburicase in tumor lysis syndrome (TLS) is described. The current standard management for TLS consists of oral allopurinol in conjunction with i.v. hydration with or without alkalinization...
  96. ncbi Emergency care: the tumor lysis syndrome
    Ecaterina Turtureanu-Hanganu
    University Hospital Sf Spiridon, Medical Clinic of Hematology, School of Medicine, University of Medicine and Pharmacy Gr T Popa, Iasi
    Rev Med Chir Soc Med Nat Iasi 106:705-11. 2002
    The Tumor Lysis Syndrome (TLS) is a constellation of metabolic disturbances due to the rapid tumoral cell destruction, either spontaneous or induced by cytoreduction therapy, which manifests as an acute, subacute or chronic renal ..
  97. ncbi Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach
    Hsiang Hao Hsu
    Department of Nephrology, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan
    J Nephrol 17:50-6. 2004
    Acute spontaneous tumor lysis syndrome (STLS) presenting with hyperuricemic acute renal failure (ARF) is a rare disease which can be overlooked in patients with neoplasic disorders, requiring prompt recognition and aggressive management...
  98. ncbi Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study
    Andre Bosly
    Cliniques Universitaires, Avenue Dr Therasse 1, B 5530 de Mont Godinne, Belgium
    Cancer 98:1048-54. 2003
    Hyperuricemia and tumor lysis syndrome (TLS) are serious complications that can occur during chemotherapy for hematologic malignancies, even if standard management procedures, including administration of allopurinol, are undertaken...
  99. ncbi European experience in the treatment of hyperuricemia
    C Patte
    Pediatric Oncology Department, Institut Gustave-Roussy, Villejuif, France
    Semin Hematol 38:9-12. 2001
    ..management of non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL), and for prevention of tumor lysis syndrome (TLS)...
  100. ncbi Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia
    B D Cheson
    Cancer Therapy Evaluation Program, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:2313-20. 1998
    To quantify the incidence and severity of tumor lysis syndrome (TLS) as a consequence of fludarabine therapy in patients with advanced chronic lymphocytic leukemia (CLL).
  101. ncbi Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience
    C H Pui
    St. Jude Children's Research Hospital, and Department of Pediatrics, University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Semin Hematol 38:13-21. 2001
    ..These data suggest that recombinant urate oxidase is safe and effective in the prophylaxis and treatment of hyperuricemia associated with malignancy or chemotherapy...

Research Grants10

  1. Preclinical Development of Uricase-PEG 20
    JOHN BOMALASKI; Fiscal Year: 2002
    ..Severe hyperuricemia can occur following cancer chemotherapy (tumor lysis syndrome) and organ transplantation (most common in heart and kidney transplant patients) which may result in acute ..
  2. Nonablative AlloSCT in Refractory Autoimmune Disease
    Mitchell Cairo; Fiscal Year: 2003
    ....
  3. First Int'l Symposium on Childhood and Adolescent NHL
    Mitchell Cairo; Fiscal Year: 2003
    ..abstract_text> ..
  4. A Phase I Study of Single Agent Flavopiridol in B-Cell *
    Thomas Lin; Fiscal Year: 2007
    ..Finally, we will examine whether acute infusion toxicity to flavopiridol is accompanied by release of inflammatory cytokines such as TNF-a, IFN-y, IL-6, IL-8 and IL-10. [unreadable] [unreadable] [unreadable]..
  5. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2006
    ..abstract_text> ..
  6. A Novel Dosing Schedule of Flavopiridol in CLL
    Thomas Lin; Fiscal Year: 2006
    ..We hypothesize that this dosing schedule will modulate pharmacodynamic targets and show clinical activity. We plan to proceed to phase II studies of this schedule in high-risk CLL patients. [unreadable] [unreadable]..
  7. A Phase I Study of the AKT Inhibitor 17-AAG in CLL
    Thomas Lin; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  8. Antiproliferative Rx for venous neointimal hyperplasia
    Prabir Roy Chaudhury; Fiscal Year: 2005
    ..We believe that the results from this study could transform the clinical care of hemodialysis patients and at the same time result in the successful clinical application of local therapy for the treatment of neointimal hyperplasia...
  9. PEDIATRIC ONCOLOGY GROUP
    Yaddanapudi Ravindranath; Fiscal Year: 2002
    ....
  10. Monoclonal Antibody Therapy in B-Cell CLL.
    Thomas Lin; Fiscal Year: 2008
    ..Correlative studies to assess tumor resistance factors will be conducted, to provide insight for development of future antibodies and combination regimens. ..